Welcome to the e-CCO Library!

P422: Patient-near Infliximab trough-level testing by a novel quantitative rapid test; the Quantum Blue Infliximab assay
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Roseth A.*1, Lindsjô I.2, Malmstrøm G.-H.3

Created: Wednesday, 20 February 2019, 10:36 AM
P422: Risks and clinical features of active tuberculosis developed in patients with inflammatory bowel disease receiving anti-tumour necrosis factor therapy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. W. Lee, C. H. Choi*

Created: Friday, 22 February 2019, 9:49 AM
P422: Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1
Year: 2018
Source: ECCO '18 Vienna
Authors:

E.V. Loftus1, B.E. Sands2, J.-F. Colombel3, I. Dotan4, J.M. Khalid5, D. Tudor6, P. Geransar7*

Created: Thursday, 21 February 2019, 9:14 AM
P422: Transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Todeschini, A.(1)*;Geccherle, A.(1);Signoretto, P.(1);Fasoli, E.(1);Variola, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P423 NF-kB as a prognostic marker of response to biologic therapy in children with IBD
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Radigina1, A. Illarionov2, D. Kuptsova1, A. Potapov3, S. Petrichuk1, A.P. Fisenko1

Created: Thursday, 30 January 2020, 10:12 AM
P423: Azathioprine still remains the first step-up therapy in patients with Inflammatory Bowel Disease in low-middle income countries.
Year: 2022
Source: ECCO'22
Authors: Ranjan, M.K.(1);Kumar, P.(1);Vuyyuru, S.K.(1);Kante, B.(1);Sahu, P.(1);Mundhra, S.(1);Golla, R.(1);Singh, M.(1);Virmani, S.(1);Sharma, R.(1);Panwar, R.(1);Das, P.(1);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
Created: Friday, 11 February 2022, 3:52 PM
P423: Comparative efficacy of anti-tumour necrosis factor agents and vedolizumab in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Subramanian*1, R. Davis1, P. MacParland1, S. Dodd2, D. Storey1, C. Probert1, P. Collins1, T. Skouras1, A. Steel1, E. Derbyshire1, M. Dibb1

Created: Friday, 22 February 2019, 9:41 AM
P423: Early improvement in quality of life in patients with luminal Crohn's disease treated with adalimumab. Data from RAPIDA trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Casellas F.*1, Barreiro-de Acosta M.2, Esteve M.3, Castro-Laria L.4, Vicente R.5, Ceballos D.6, Echarri A.7, Martín-Arranz M.D.8, Busquets D.9, Llaό J.10, Navarro-Llavat M.11, Huguet J.M.12, Argüelles-Arias F.4, Boudet J.M.5, Rodríguez-San Pedro L.13, Díaz G.13, Casado R.13, Marín I.14

Created: Wednesday, 20 February 2019, 10:36 AM
P423: Effect of tofacitinib on colectomy risk in anti TNF-alfa refractory ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Romeo, S.(1)*;Carvalhas Gabrielli, A.M.(1);Ferretti, F.(2);Piazza O Sed, N.(3);Mazzola, A.M.(4);Alicante, S.(1);Berté, R.(1);Scribano, M.L.(5);Buscarini, E.(1);Ricci, C.(4);Caprioli, F.(3,6);Ardizzone, S.(2);Cannatelli, R.(2);
Created: Friday, 14 July 2023, 11:05 AM
P423: Epidemiology, diagnostic work-up and pharmacological requirements of inflammatory bowel disease (IBD) in Spain: Results from the nationwide EpidemIBD study of GETECCU
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Chaparro1,2,3,4*, J.L. Cabriada5, M.J. Casanova1,2,4, D. Ceballos6, M. Esteve4,7, H. Fernández8, M. Barreiro-de Acosta9, V. García-Sánchez10,11, D. Ginard12, F. Gomollón4,13,14, R. Llorente Poyatos15, P. Nos4,16, S. Riestra17, M. Rivero18, P. Robledo19, C. Rodríguez Gutiérrez20, B. Sicilia21, E. Torrella22, F. Rodríguez-Artalejo23,24,25, J.P. Gisbert1,2,3,4, on behalf of the EpidemIBD group

Created: Thursday, 21 February 2019, 9:14 AM
P423: Paediatric Crohn’s disease patients with refractory psoriasis treated with a combination of infliximab and ustekinumab
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Olbjørn*1, 2, J. B. Rove1, J. Jahnsen2, 3

Created: Friday, 22 February 2019, 9:49 AM
P423: Treatment escalation and associated cost in German Ulcerative Colitis patients treated with advanced therapies
Year: 2021
Source: ECCO'21 Virtual
Authors: Picker, N.(1);Patel, H.(2);Wilke, T.(3);Rosin, L.(4);Bokemeyer, B.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P424 Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. FISCHER1, M. Oppe2, S. Stypa1, V. Lukyanov3, I. Petrakis4

Created: Thursday, 30 January 2020, 10:12 AM
P424: Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Parra R.S., Feitosa M.R., Féres O., Rocha J.J.R.d.

Created: Wednesday, 20 February 2019, 10:36 AM
P424: Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Madero Velázquez, L.(1)*;Jovani, V.(2);Andrés, M.(3);Más, P.(4);Aguas, M.(5);Vicens, E.(6);Ojeda, A.(7);Noguera-Pons, J.R.(8);Ranieri, L.(9);Zabana, Y.(10);Pujol, M.(11);Barreiro de Acosta, M.(12);Pérez-Pampin, E.(13);Bernal, L.(14);Belen, O.(14);Moreno, V.(14);García, M.F.(15);Sempere, L.(1);Zapater, P.(16);Gutiérrez Casbas, A.(17);
Created: Friday, 14 July 2023, 11:05 AM
P424: Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Calafat*1, M. Mañosa1,2, E. Ricart2,3, E. Iglesias4, M. Calvo5, F. Rodríguez-Moranta6, C. Taxonera7, P. Nos2,8, F. Mesonero9, M. Martín-Arranz10, M. Mínguez11, J. P. Gisbert2,12, S. García-López13, R. de Francisco14, F. Gomollón2,15, X. Calvet2,16, E. García-Planella17, M. Rivero18, J. Martínez-Cadila19, F. Argüelles20, L. Arias21, M. Cimavilla22, Y. Zabana2,23, F. Cañete1,2, E. Cabré1,2, E. Domènech1,2, ENEIDA Registry of GETECCU1

Created: Friday, 22 February 2019, 9:41 AM
P424: Monitoring response to adalimumab therapy in Crohn’s disease patients by bowel ultrasound: Sub-analysis from TRUST
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Kucharzik1*, C. Maaser2, U. Helwig3, N. Börner4, J. Gronych5, A. Rössler5, S. Rath5, TRUST Study Group

Created: Thursday, 21 February 2019, 9:14 AM
P424: Surgery for children with Crohn’s disease.
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Stefanowicz*1, H. Ismail1, G. Kowalewski1, A. Kowalski1, J. Kierkuś2, P. Kaliciński1

Created: Friday, 22 February 2019, 9:49 AM
P424: Treatment persistence of first-line anti-TNF therapy in patients with inflammatory bowel diseases: results from a real-world study over 20 years
Year: 2021
Source: ECCO'21 Virtual
Authors: Blesl, A.(1);Binder, L.(1);Högenauer, C.(1);Wenzl, H.(1);Borenich, A.(2);Pregartner, G.(2);Berghold, A.(2);Mestel, S.(1);Kump, P.(1);Baumann-Durchschein, F.(1);Petritsch, W.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P424: Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations
Year: 2022
Source: ECCO'22
Authors: Alice, H.(1);Gemma, B.(1);Selinger, C.P.(1);
Created: Friday, 11 February 2022, 3:52 PM